title: Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
abstract: Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.
authors.affiliation: aDepartment of Psychiatry, Seoul National University College of Medicine bDepartment of Brain and Cognitive Sciences, College of Natural Sciences, Seoul National University cDepartment of Neuropsychiatry, Seoul National University Hospital dDepartment of Neuropsychiatry, SMG-SNU Boramae Medical Center eDepartment of Neuropsychiatry, Korea University Anam Hospital fDepartment of Neuropsychiatry, The Catholic University of Korea Yeouido St Mary's Hospital gMedical Affairs, Janssen, Seoul hDepartment of Neuropsychiatry, College of Medicine, Chungbuk National University, Cheongju iDepartment of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam jDepartment of Neuropsychiatry, Gachon University Gil Hospital, Incheon kDepartment of Neuropsychiatry, Inje University Ilsan Paik Hospital, Goyang lDepartment of Neuropsychiatry, Korea University Ansan Hospital, Ansan mDepartment of Neuropsychiatry, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu nDepartment of Neuropsychiatry, Dankook University Hospital, Cheonan, Republic of Korea.
authors.forename: Jun Soo
authors.initials: JS
authors.lastname: Kwon
authors.forename: Sung Nyun
authors.initials: SN
authors.lastname: Kim
authors.forename: Jaewook
authors.initials: J
authors.lastname: Han
authors.forename: Sang Ick
authors.initials: SI
authors.lastname: Lee
authors.forename: Jae Seung
authors.initials: JS
authors.lastname: Chang
authors.forename: Jung-Seok
authors.initials: JS
authors.lastname: Choi
authors.forename: Heon-Jeong
authors.initials: HJ
authors.lastname: Lee
authors.forename: Seong Jin
authors.initials: SJ
authors.lastname: Cho
authors.forename: Tae-Youn
authors.initials: TY
authors.lastname: Jun
authors.forename: Seung-Hwan
authors.initials: SH
authors.lastname: Lee
authors.forename: Changsu
authors.initials: C
authors.lastname: Han
authors.forename: Kyoung-Uk
authors.initials: KU
authors.lastname: Lee
authors.forename: Kyung Kyu
authors.initials: KK
authors.lastname: Lee
authors.forename: EunJung
authors.initials: E
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D000068882:Paliperidone Palmitate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011569:Psychiatric Status Rating Scales; D056910:Republic of Korea; D012559:Schizophrenia / Q000188:drug therapy*; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D000068882:Paliperidone Palmitate